In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ohara Pharmaceutical Co. Ltd.

Latest From Ohara Pharmaceutical Co. Ltd.

BTG Gains First U.S. Approval With Methotrexate Antidote Voraxaze

Transatlantic specialty pharma BTG adds to its antidote portfolio with FDA approval of Voraxaze, an enzyme drug that breaks down methotrexate in patients whose kidneys are failing due to high serum levels of the chemotherapeutic. BTG also markets snake-bite therapy CroFab and DigiFab for digitalis overdose and recently licensed a late-stage drug to counter toxicity from 5-FU chemotherapy.


EUSA Wins U.S. Approval of Erwinaze; Shipping To Start Week Of Nov. 20

Eusa hopes the approval will help cement its efforts in the U.S., where it has been trying to build a strong presence for several years.

BioPharmaceutical Launches

Deals Shaping the Medical Industry (09/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Ohara Pharmaceutical Co. Ltd.
  • Senior Management
  • Seiji Ohara, PhD, Pres. & CEO
  • Contact Info
  • Ohara Pharmaceutical Co. Ltd.
    Phone: (81) 748 88 2200
    121-15 Toriino Koka-cho
    Shiga, 520-3403